This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Disease modifying therapy in secondary progressive MS

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The goal of disease modifying therapy in secondary progressive multiple sclerosis is to delay the progression of disability.

Interferon-beta1b has been shown in one randomised double blind placebo controlled multicentre trial to significantly increase the time to confirmed neurological deterioration.

Interferon-beta1b is licensed in Europe for secondary progressive MS.

NICE state (1,2):

  • Interferon beta-1b (Extavia) is recommended as an option for treating multiple sclerosis, only if:
    • the person has relapsing-remitting multiple sclerosis and has had 2 or more relapses within the last 2 years or
    • the person has secondary progressive multiple sclerosis with continuing relapses and the company provides it according to the commercial arrangement

  • Siponimod is recommended, within its marketing authorisation, as an option for treating secondary progressive multiple sclerosis with evidence of active disease (that is, relapses or imaging features of inflammatory activity) in adults
    • recommended only if the company provides siponimod according to the commercial arrangement


  • Siponimod is a second-generation sphingosine-1-phosphate (S1P) receptor modulator - study evidence suggests that siponimod may prevent synaptic neurodegeneration and promote remyelination in the CNS


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.